Newsroom | 50856 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced a poster presentation related to the company’s work on VE303, its defined bacterial consortium candidate for the prevention of recurrent Clostridioides difficile infection (CDI), and an oral presentation on VE707, its defined bacterial consortium candidate for the prevention of Gram-negative infections,...

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical a...

CHICAGO--(BUSINESS WIRE)--Emalex Biosciences received a patent covering an orally disintegrating tablet (ODT) formulation of ecopipam, an investigational D1 antagonist...

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced the publication of a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology demonstrating that its neuro-symbolic, multi-agent artificial intelligence platform can match cancer patients to clinical trials four times faster than conventional methods, with measurable accuracy, transparency, and equity, in routine clinical practice. The study, "Transforming oncology clinical t...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research study led by Dr. David Beers and Dr. Stanley Appel at the Houston Methodist Neurological Institute. The study included the longitudinal measurement of well-characterized serum biomarkers of lipid peroxidation (4-hydroxy-2-nonenal [4-HNE]), systemic inflammation (lipopolys...

MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced p...

CLEVELAND & DALLAS--(BUSINESS WIRE)--Align Capital Partners’ (“ACP”) drug and alcohol testing solutions provider Premier Biotech (“Premier” or the “Company”) has acquired GH Solutions (“GH”), a distributor of point-of-care diagnostic testing products. GH Solutions serves customers across the United States, primarily in the government and workplace end markets. This combination increases Premier’s customer base and broadens the solutions that GH can offer to its existing network. GH’s dedication...

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16th, 2026 at 12:45 p.m. ET. The live webcast of the presentation may be accessed via the Events and Presentations section of the Sensei website at investors.senseibio.com. A replay of the webcast will be available for approximately 90 days following the event. About Sensei Biotherapeutics Sensei Bio...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Thursday, April 16, 2026 at 3:00 PM EDT Webcast...